Stocktoria
ELITE PHARMACEUTICALS INC /NV/ ELTP
OTC · OOTC · stock · Pharmaceutical Preparations · website · IPO 2014-02-20
ELITE PHARMACEUTICALS INC /NV/ financials (annual, from 10-K)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M | $25.4M | $18.0M | $7.6M | $7.5M | $9.6M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M | $14.8M | $11.9M | $8.0M | $2.9M | $3.9M | $3.7M |
| R&D expense | $5.7M | $8.0M | $6.9M | $6.2M | $4.1M | $5.1M | $5.5M | $7.6M | $9.6M | $8.3M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.7M | $5.1M | $2.1M | -$2.3M | -$9.2M | -$9.1M | -$7.4M |
| Interest expense | — | — | $588,622 | $1.1M | $191,816 | $259,598 | $355,874 | $369,173 | $335,498 | $238,223 |
| Income tax | $11.9M | $4.3M | -$19.6M | $424,028 | -$1.7M | — | — | -$676,016 | -$1.0M | -$1.9M |
| Net income | $44.9M | -$4.3M | $20.1M | $3.6M | $8.9M | $5.1M | -$2.2M | -$9.3M | -$3.7M | $3.8M |
| EPS (diluted) | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 | $0.00 | $0.00 | $-0.01 | $-0.01 | $-0.01 |
| Operating cash flow | $23.7M | $7.5M | -$3.2M | $3.3M | $6.5M | $3.2M | -$1.8M | -$6.8M | -$4.8M | -$7.9M |
| Free cash flow | $22.8M | $5.8M | -$4.0M | -$2.4M | $6.0M | — | — | — | — | — |
| Cash & equivalents | — | — | $7.1M | $7.8M | $8.5M | $3.2M | $1.1M | $2.3M | $7.2M | $10.6M |
| Inventory | $21.3M | $16.2M | $12.9M | $9.6M | $6.7M | $5.0M | $4.1M | $4.5M | $4.9M | $6.4M |
| Total assets | $138.3M | $96.4M | $83.7M | $40.9M | $35.1M | $26.2M | $25.0M | $24.4M | $30.9M | $34.3M |
| Total liabilities | $39.4M | $42.9M | $26.1M | $11.9M | $9.9M | $10.0M | $14.3M | $13.0M | $12.4M | $8.6M |
| Shareholders' equity | $98.9M | $53.5M | $57.6M | $29.0M | $25.2M | $16.2M | $10.7M | -$2.5M | $4.6M | $25.7M |
Growth · year-over-year · Revenue CAGR 35.5%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +77.1% | +48.4% | +65.8% | +5.9% | +27.1% | +41.0% | +137.8% | +1.5% | -22.6% | -22.9% |
| Net income growth | — | -121.5% | +464.6% | -60.0% | +74.9% | — | — | — | -196.4% | — |
| EPS growth | — | -100.0% | — | -100.0% | — | — | — | — | — | — |
| Free cash flow growth | +291.4% | — | — | -139.9% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001053369 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.